FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2514572142> ?p ?o ?g. }

• W2514572142 endingPage "552" @default.
• W2514572142 startingPage "552" @default.
• W2514572142 abstract "Abstract Purpose The pediatric-inspired intensified GRAALL protocol yielded a marked improvement in the outcome of adults with Ph-negative acute lymphoblastic leukemia (ALL) (Huguet et al,JCO 2009), raising the issue of the place of allogeneic HSCT in this new context. We report here the results associated with HSCT in first complete remission (CR) in younger adults treated in the GRAALL-2003/2005 trials. Patients and methods In these trials, HSCT was offered in first CR to patients aged 15-55 years with ALL at higher risk of relapse. High-risk factors included white blood count >30 x 109/L for B-lineage ALL, central nervous system (CNS) involvement, t(4;11)/MLL anomalies, t(1;19), low hypodiploidy/near triploidy, complex karyotype, early resistance to the steroid prephase (CsR), early resistance to chemotherapy (ChR) as assessed by poor bone marrow blast clearance at day 8, and late CR. Per protocol, HSC donor should be a matched sibling or an unrelated donor (10/10 or eventually 9/10 HLA matched) and conditioning regimen should include single fraction 10-Gy or fractionated 12-Gy total body irradiation (TBI) and high-dose cyclophosphamide. The role of HSCT was evaluated by HSCT versus no-HSCT cohort comparison (Mantel-Byar time-dependent analysis). Results Among the 522 high-risk patients eligible, 283 (54%) actually received HSCT in first CR (185 B-lineage and 98 T-lineage ALL; median age, 31 years). There were no significant differences in baseline characteristics and early response between HSCT and no-HSCT cohorts, except more HSCT patients with t(4;11)/MLL anomalies. Among the 283 HSCT patients, 46 had t(4;11)/MLL anomalies, 13 had CNS disease, 116 had CsR and 176 had ChR ALL. Origin of HSC was 140 sibling and 143 unrelated donors, including 47 unrelated donors with 1 HLA mismatch. The following HSCT protocol violations were observed: a) conditioning did not include TBI in 17 patients; b) 10 patients received reduced-intensity conditioning (RIC); and c) 13 patients received cord blood HSCT. These patients remained in the HSCT cohort for the analysis. With a median post-transplant follow-up of 3.5 years, post-HSCT cumulative incidence of relapse (CIR), non-relapse mortality (NRM) and relapse-free survival (RFS) were estimated respectively at 19% (95% CI, 15-25), 16% (95% CI, 12-21) and 64% (95% CI, 58-70) at 3 years, without any RFS difference between sibling and unrelated donors. A marked trend for a higher NRM was observed in patients aged 45 years or more (26% versus 13% at 3 years; HR, 1.6; p=0.059), while post-transplant CIR was similar in older and younger patients. Mantel-Byar RFS estimations showed no significant difference between both HSCT and no-HSCT cohorts (HR, 0.80; p=0.13), meaning that the risk factors used in these protocols failed to identify patients who could significantly benefit from HSCT in first CR. As minimal residual disease (MRD) had a major prognostic impact, we retrospectively analyzed the effect of HSCT in the 278/522 patients evaluated for 6-week Ig/TCR MRD level (154 HSCT and 124 no-HSCT patients, including 92 and 62 patients with MRD >=10-4, respectively). Mantel-Byar RFS estimations showed that HSCT did not benefit to patients with MRD <10-4 (HR, 1.2; p=0.67) as opposed to those with MRD >=10-4 (HR, 0.6; p=0.02), with a positive HSCT-by-MRD interaction (p=0.04) (Figure 1). Conclusion In adult patients with high-risk ALL in first CR treated in the GRAALL-2003/2005 trials, myeloablative allogeneic HSCT from sibling and unrelated donors was associated with a 64% RFS at 3 years. The 26% NRM observed at 3 years in patients aged 45 years or more suggests considering RIC-HSCT in these patients. MRD response appears to be a powerful tool to select patients who might benefit from HSCT. This selection tool will be prospectively evaluated in the next GRAALL-2013 trial. ND and AH contributed equally to the work. Disclosures: No relevant conflicts of interest to declare." @default.
• W2514572142 created "2016-09-16" @default.
• W2514572142 creator A5000000264 @default.
• W2514572142 creator A5000436961 @default.
• W2514572142 creator A5007895303 @default.
• W2514572142 creator A5009193536 @default.
• W2514572142 creator A5011668592 @default.
• W2514572142 creator A5011865826 @default.
• W2514572142 creator A5017435311 @default.
• W2514572142 creator A5022161221 @default.
• W2514572142 creator A5028026658 @default.
• W2514572142 creator A5036207495 @default.
• W2514572142 creator A5037324033 @default.
• W2514572142 creator A5037455697 @default.
• W2514572142 creator A5046436694 @default.
• W2514572142 creator A5056337631 @default.
• W2514572142 creator A5064531399 @default.
• W2514572142 creator A5072557528 @default.
• W2514572142 creator A5073015935 @default.
• W2514572142 creator A5076734375 @default.
• W2514572142 creator A5078817313 @default.
• W2514572142 creator A5085953785 @default.
• W2514572142 date "2013-11-15" @default.
• W2514572142 modified "2023-10-17" @default.
• W2514572142 title "Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adults With Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL): Results From The Group For Research On Adult ALL (GRAALL)" @default.
• W2514572142 doi "https://doi.org/10.1182/blood.v122.21.552.552" @default.
• W2514572142 hasPublicationYear "2013" @default.
• W2514572142 type Work @default.
• W2514572142 sameAs 2514572142 @default.
• W2514572142 citedByCount "17" @default.
• W2514572142 countsByYear W25145721422014 @default.
• W2514572142 countsByYear W25145721422015 @default.
• W2514572142 countsByYear W25145721422017 @default.
• W2514572142 countsByYear W25145721422018 @default.
• W2514572142 countsByYear W25145721422020 @default.
• W2514572142 countsByYear W25145721422021 @default.
• W2514572142 countsByYear W25145721422022 @default.
• W2514572142 crossrefType "journal-article" @default.
• W2514572142 hasAuthorship W2514572142A5000000264 @default.
• W2514572142 hasAuthorship W2514572142A5000436961 @default.
• W2514572142 hasAuthorship W2514572142A5007895303 @default.
• W2514572142 hasAuthorship W2514572142A5009193536 @default.
• W2514572142 hasAuthorship W2514572142A5011668592 @default.
• W2514572142 hasAuthorship W2514572142A5011865826 @default.
• W2514572142 hasAuthorship W2514572142A5017435311 @default.
• W2514572142 hasAuthorship W2514572142A5022161221 @default.
• W2514572142 hasAuthorship W2514572142A5028026658 @default.
• W2514572142 hasAuthorship W2514572142A5036207495 @default.
• W2514572142 hasAuthorship W2514572142A5037324033 @default.
• W2514572142 hasAuthorship W2514572142A5037455697 @default.
• W2514572142 hasAuthorship W2514572142A5046436694 @default.
• W2514572142 hasAuthorship W2514572142A5056337631 @default.
• W2514572142 hasAuthorship W2514572142A5064531399 @default.
• W2514572142 hasAuthorship W2514572142A5072557528 @default.
• W2514572142 hasAuthorship W2514572142A5073015935 @default.
• W2514572142 hasAuthorship W2514572142A5076734375 @default.
• W2514572142 hasAuthorship W2514572142A5078817313 @default.
• W2514572142 hasAuthorship W2514572142A5085953785 @default.
• W2514572142 hasConcept C126322002 @default.
• W2514572142 hasConcept C143998085 @default.
• W2514572142 hasConcept C151730666 @default.
• W2514572142 hasConcept C203014093 @default.
• W2514572142 hasConcept C2776694085 @default.
• W2514572142 hasConcept C2776755627 @default.
• W2514572142 hasConcept C2777408962 @default.
• W2514572142 hasConcept C2778336483 @default.
• W2514572142 hasConcept C2778461978 @default.
• W2514572142 hasConcept C2778880498 @default.
• W2514572142 hasConcept C2779343474 @default.
• W2514572142 hasConcept C2781107101 @default.
• W2514572142 hasConcept C2909962599 @default.
• W2514572142 hasConcept C2911091166 @default.
• W2514572142 hasConcept C71924100 @default.
• W2514572142 hasConcept C86803240 @default.
• W2514572142 hasConcept C90924648 @default.
• W2514572142 hasConceptScore W2514572142C126322002 @default.
• W2514572142 hasConceptScore W2514572142C143998085 @default.
• W2514572142 hasConceptScore W2514572142C151730666 @default.
• W2514572142 hasConceptScore W2514572142C203014093 @default.
• W2514572142 hasConceptScore W2514572142C2776694085 @default.
• W2514572142 hasConceptScore W2514572142C2776755627 @default.
• W2514572142 hasConceptScore W2514572142C2777408962 @default.
• W2514572142 hasConceptScore W2514572142C2778336483 @default.
• W2514572142 hasConceptScore W2514572142C2778461978 @default.
• W2514572142 hasConceptScore W2514572142C2778880498 @default.
• W2514572142 hasConceptScore W2514572142C2779343474 @default.
• W2514572142 hasConceptScore W2514572142C2781107101 @default.
• W2514572142 hasConceptScore W2514572142C2909962599 @default.
• W2514572142 hasConceptScore W2514572142C2911091166 @default.
• W2514572142 hasConceptScore W2514572142C71924100 @default.
• W2514572142 hasConceptScore W2514572142C86803240 @default.
• W2514572142 hasConceptScore W2514572142C90924648 @default.
• W2514572142 hasIssue "21" @default.
• W2514572142 hasLocation W25145721421 @default.
• W2514572142 hasOpenAccess W2514572142 @default.
• W2514572142 hasPrimaryLocation W25145721421 @default.
• W2514572142 hasRelatedWork W1898982375 @default.
• W2514572142 hasRelatedWork W1977112375 @default.

• next